Tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel and lisocabtagene maraleucel are CD19-targeted CAR-T cell products, being used to treat relapsed or refractory B cell acute lymphoblastic leukemia (r/r B-ALL), and non-Hodgkin’s lymphomas (r/r NHLs) (21–24). The gene discussed is CD19; the disease is non-Hodgkin lymphoma.